There is provided a composition having an effective amount ofN-terminallytruncated galectin-3 in a pharmaceutically acceptable carrier or an effectiveamount of a nucleic acid sequence encoding N-terminally truncated galectin-3in a pharmaceutically acceptable carrier. Also provided by the presentinvention is a method of treating cancer by administering to a patient in needof such treatment an effective amount of N-terminally truncated galectin-3 ina pharmaceutically acceptable carrier or an effective amount of a nucleic acidsequence encoding N-terminally truncated galectin-3 in a pharmaceuticallyacceptable carrier. The present invention also provides an antibody thatspecifically binds to carbohydrate ligands of galectin-3. Further, there isprovided an anti-cancer treatment having an effective amount of N-terminallytruncated galectin-3 and a pharmaceutically acceptable carrier or an effectiveamount of nucleic acid sequence encoding N-terminally truncated galectin-3 ina pharmaceutically acceptable carrier.
展开▼
